Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study

Movement Disorders

Volumn 24, Issue 10, 2009, Pages 1437-1444

  Rodriguez Oroz, Maria C ^a,b,c   Lage, Pablo Martínez ^a,f   Sanchez Mut, Jose ^d,g   Lamet, Isabel ^a   Pagonabarraga, Javier ^c,e   Toledo, Jon B ^a   García Garcia, David ^a,b,c   Clavero, Pedro ^a,b,c   Samaranch, Lluis ^a   Irurzun, Cecilia ^a   Matsubara, Juan M ^a   Irigoien, Jaione ^a   Bescos, Emilia ^a   Kulisevsky, Jaime ^c,e   Pérez Tur, Jordi ^c,d   Obeso, Jose A ^a,b,c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^e Sant Pau University Hospital   (Spain)

^f Fundacion ACE   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Dementia; Genetics; Homocysteine; Mild cognitive impairment; Parkinson's disease; White matter hyperintensities

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CABERGOLINE; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; PERGOLIDE; PRAMIPEXOLE; PYRIDOXINE; ROPINIROLE;

ADULT; AGED; AMINO ACID METABOLISM; ARTICLE; BIOCHEMISTRY; BLESSED DEMENTIA SCALE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIVING IN DEMENTIA SCALE; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERIATRIC DEPRESSION RATING SCALE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; AGED; AGED, 80 AND OVER; BRAIN; CARBON-NITROGEN LIGASES; CASE-CONTROL STUDIES; COGNITION DISORDERS; CYSTATHIONINE BETA-SYNTHASE; DEPRESSION; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; IMMUNOASSAY; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; VITAMIN B 12; VITAMIN B 6;

EID: 69849093882     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22522     Document Type: Article

References (45)

1. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.
2. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-1263.
3. Prins ND, Den Heijer T, Hofman A, et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 2002;59:1375-1380.
4. Quadri P, Fragiacomo C, Pezzati R, et al. Homocysteine and B vitamins in mild cognitive impairment and dementia. Clin Chem Lab Med 2005;43:1096-1100.
5. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
6. Bertsch T, Mielke O, Holy S, et al. Homocysteine in cerebrovascular disease: an independent risk factor for subcortical vascular encephalopathy. Clin Chem Lab Med 2001;39:721-724.
7. Tiemeier H, van Tuijl HR, Hofman A, et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099-2101.
8. Miller JW, Selhub J, Nadeau MR, et al. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003;60:1125-1129.
9. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-227.
10. Religa D, Czyzewski K, Styczynska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 2006;404:56-60.
11. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60: 59-64.
12. Kuhn W, Hummel T, Woitalla D, Muller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2001;56:281; author reply281-282.
13. Yasui K, Kowa H, Nakaso K, et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-440.
14. Todorovic Z, Dzoljic E, Novakovic I, et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006;248:56-61.
15. McIlroy SP, Dynan KB, Lawson JT, et al. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-2356.
16. Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006;66:1941-1943.
17. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005;11:131-133.
18. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005;20:69-72.
19. Muller T, Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 2006;62:447-450.
20. Valkovic P, Benetin J, Blazicek P, et al. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005;11:253-256.
21. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-891.
22. Ozer F, Meral H, Hanoglu L, et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 2006;28:853-858.
23. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61:865-868.
24. Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006;29:305-311.
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
26. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
27. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
28. Blessed G, Tomlinson BE, Roth M. Blessed-Roth Dementia Scale (DS). Psychopharmacol Bull 1988;24:705-708.
29. Teunisse S, Derix MM, van Crevel H. Assessing the severity of dementia. Patient and caregiver. Arch Neurol 1991;48:274-277.
30. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
31. Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988;38:900-903.
32. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
33. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia: Lea and Febiger; 1983.
34. Raven J, Court J. Standard progressive matrices. Raven manual: section 3. Oxford: Oxford Psychologist Press; 1992.
35. Parkin AJ. Exploraciones en Neuropsicologia cognitiva. Madrid: Panamelicana; 1999.
36. Shum DK, MK, Bain J. Construct validity of eight tests of attention:comparison of normal and closed head injured samples. The Clinical Neuropsychologist. 1990;4:151-162.
37. Golden CJ. Stroop color and word test. A manual for clinical and experimental use. Chicago: Skoelting; 1978.
38. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322.
39. Zoccolella S, Lamberti P, Iliceto G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005;43:1107-1110.
40. Barone P, Burn DJ, van Laar T, et al. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008;23:1532-1540.
41. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-1349.
42. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
43. Garde E, Mortensen EL, Krabbe K, et al. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 2000;356:628-634.
44. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm Suppl 2004:15-20.
45. Nakaso K, Yasui K, Kowa H, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 2003;207:19-23.